Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cellmid (CDY) subsidiary, Advangen, has signed a distribution agreement with Tru Beauty Concepts for its anti-aging hair care products, évolis
  • Tru Beauty is a salon distributor that services 40,000 salons across the U.S.
  • Under the agreement, Tru Beauty will sell the évolis range to salons in northeast America for five years
  • Cellmid is up four per cent on the market today and shares are trading for 13 cents per share

Cellmid (CDY) subsidiary, Advangen, has signed a distribution agreement with Tru Beauty Concepts for its anti-aging hair care products, évolis.

Tru Beauty is a salon distributor and national educator, servicing 40,000 salons through the United States.

Under the agreement, Tru Beauty will sell the évolis range to salons in northeast America for five years.

évolis will also be listed on the Salon Interactive portal, which is an e-commerce hub for hair salons across the U.S. This deal is expected to result in significant revenue growth in the U.S. business during the second half of the 2021 financial year.

CEO Maria Halasz says this agreement is a "game-changer."

"Securing salon distribution will add scale to our U.S. expansion and growth ambitions for the brand," she added.

The deal comes as consumer health services in the U.S. increased by 51 per cent to $626,000 over FY20.

Cellmid is up four per cent on the market this afternoon and shares are trading for 13 cents per share at 1:26 pm AEST.

CDY by the numbers
More From The Market Herald
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon - The Market Herald

" Little Green Pharma (ASX:LGP) pursues global expansion over June quarter

Little Green Pharma (LGP) celebrated backing from Gina Rhineheart and a major medicinal cannabis facility purchase over the June quarter but noted subdued

" Chimeric Therapeutics (ASX:CHM) obtains licence for solid tumour cell therapy

Chimeric Therapeutics (CHM) has obtained the exclusive licence to a novel treatment for solid tumours from the University of Pennsylvania.  
AnteoTech (ASX:ADO) - CEO, Derek Thomson - The Market Herald

" AnteoTech (ASX:ADO) strikes UK distribution deal for COVID-19 test tech

Surface chemistry company AnteoTech (ADO) has struck its first European distribution deal for its EuGeni rapid diagnostic test (RDT) technology.
Medlab Clinical (ASX:MDC) - CEO, Dr Sean Hall - The Market Herald

" Medlab Clinical (ASX:MDC) gets green light for US patent

Medlab Clinical (MDC) has been issued with a notice of allowance by the United States Patent Office (USPTO) regarding a patent for its